Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Clinical Trials

Find Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Clinical Trials Near You

CAN-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The CAN-PRIME Study is to test the safety and functionality of Neuralink's N1 Implant and R1 Robot in people who have difficulty moving their arms and legs (tetraparesis or tetraplegia). The N1 Implant is a small, wireless device placed in the skull. It connects to tiny threads inserted into the brain by the R1 Robot, which is a machine designed to carefully place these threads. This study will help researchers learn how well the implant and robot work and if they are safe for use.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:

• Severe quadriplegia (tetraplegia) due to spinal cord injury or amyotrophic lateral sclerosis (ALS) for at least 1 year without improvement, where quadriplegia is defined as having very limited or no hand, wrist, and arm movement and all levels below

• Life expectancy ≥ 12 months.

• Ability to communicate in English

• Presence of a stable caregiver

Locations
Other Locations
Canada
University Health Network
RECRUITING
Toronto
Contact Information
Primary
Neuralink Clinical Team
clinical-team-ct@neuralink.com
(877) 398-4465
Time Frame
Start Date: 2024-11-20
Estimated Completion Date: 2030-11-30
Participants
Target number of participants: 6
Treatments
Other: CAN-PRIME: Precise Robotically Implanted Brain-Computer Interface
Open label
Sponsors
Leads: Neuralink Corp
Collaborators: University Health Network, Toronto

This content was sourced from clinicaltrials.gov